Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

J Allergy Clin Immunol. 2020 Jul;146(1):213-215. doi: 10.1016/j.jaci.2020.05.002. Epub 2020 May 11.
No abstract available

Publication types

  • Clinical Study
  • Letter

MeSH terms

  • Administration, Intravenous
  • Adult
  • Antirheumatic Agents / administration & dosage*
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy*
  • Female
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / administration & dosage*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein